Hepatology Forum最新文献

{"title":"Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score's prediction factor for survival?","authors":"Sami Evirgen,&nbsp;Bilger Cavus,&nbsp;Suut Gokturk,&nbsp;Raim Iliaz,&nbsp;Zeynep Gozde Ozkan,&nbsp;Bulent Baran,&nbsp;Asli Ciftcibası Ormeci,&nbsp;Ozlem Mutluay Soyer,&nbsp;Cetin Karaca,&nbsp;Kadir Demir,&nbsp;Selman Fatih Besisik,&nbsp;Arzu Poyanli,&nbsp;Filiz Akyuz,&nbsp;Sabahattin Kaymakoglu","doi":"10.14744/hf.2022.2022.0036","DOIUrl":"10.14744/hf.2022.2022.0036","url":null,"abstract":"<p><strong>Background and aim: </strong>Radioembolization (RE) is a one of the palliative treatments that have been used to down stage and/or increase the survival time in intermediate-advanced stages of HCC. We aimed to evaluate the clinical impact of RE and the clinical use of the albumin-bilirubin (ALBI) score as a predictor for survival in HCC patients.</p><p><strong>Materials and methods: </strong>Fifty-nine unresectable hepatocellular carcinoma (HCC) patients were enrolled. RE was performed in 28 of them (group 1) and 31 patients were followed up in the natural course (NC) (group 2). Patients were classified according to the Child-Pugh score (only cirrhotic patients), Barcelona clinic liver cancer (BCLC) staging, and ALBI scores were also calculated.</p><p><strong>Results: </strong>All patients in Group 1 were cirrhotic and their BCLC stages were as follows: 60.7% stage B and 39.3% stage C. In Group 2, 83.9% of patients were cirrhotic and their BCLC stages were as follows: 9.7% stage B, 51.6% stage C, and 38.7% stage D. Mortality rates were 82% and 100% in Groups 1 and 2, respectively. The median overall survival (OS) was 13.5 months (95% CI: 10.4-16.6 months) and 4.5 months (95% CI: 3.5-5.5 months) in Groups 1 and 2, respectively (p=0.000). When RE was applied to patients with ALBI Grade 1 and 2, the median OS was statistically higher than in the NC group, respectively (p<0.001, p<0.001).</p><p><strong>Conclusion: </strong>RE is an effective treatment method at the advanced stages of HCC. The ALBI score is a more useful and practical than the other prognostic tools.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/08/hf-4-103.PMC10564249.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease.","authors":"Yusuf Yilmaz, Eda Kaya","doi":"10.14744/hf.2022.2022.0044","DOIUrl":"10.14744/hf.2022.2022.0044","url":null,"abstract":"","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/6f/hf-4-I.PMC10209980.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9546229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.","authors":"Yusuf Yilmaz,&nbsp;Mujdat Zeybel,&nbsp;Gupse Adali,&nbsp;Arif Mansur Cosar,&nbsp;Elif Sertesen,&nbsp;Hale Gokcan,&nbsp;Halil Ibrahim Bahcecioglu,&nbsp;Mustafa Sahin,&nbsp;Cansin Tulunay,&nbsp;Ihsan Ergun,&nbsp;Ilker Turan,&nbsp;Ilkay Sedakat Idilman,&nbsp;Cigdem Celikel,&nbsp;Hale Kirimlioglu,&nbsp;Gulen Akyol,&nbsp;Funda Yilmaz,&nbsp;Cenk Sokmensuer,&nbsp;Hakan Guveli,&nbsp;Ulus Salih Akarca,&nbsp;Umit Akyuz,&nbsp;Volkan Genc,&nbsp;Murat Akyildiz,&nbsp;Nuray Yazihan,&nbsp;Engin Tutar,&nbsp;Fehmi Ates,&nbsp;Dinc Dincer,&nbsp;Yasemin Balaban,&nbsp;Murat Kiyici,&nbsp;Meral Akdogan,&nbsp;Abdullah Sonsuz,&nbsp;Ramazan Idilman,&nbsp;Suna Yapali,&nbsp;Hakan Dursun,&nbsp;Murat Aladag,&nbsp;Ilhan Satman,&nbsp;Musturay Karcaaltincaba,&nbsp;Cigdem Arikan,&nbsp;Fulya Gulerman,&nbsp;Ayse Selimoglu,&nbsp;Hasan Ozen,&nbsp;Metin Basaranoglu,&nbsp;Tarkan Karakan,&nbsp;Alper Yurci,&nbsp;Kadir Demir,&nbsp;Mehmet Koruk,&nbsp;Ahmet Uygun,&nbsp;Orhan Sezgin,&nbsp;Sadi Gulec,&nbsp;Fatih Besisik,&nbsp;Halis Simsek,&nbsp;Sadettin Hulagu,&nbsp;Nurdan Tozun,&nbsp;Adil Mardinoglu,&nbsp;Mehmet Demir,&nbsp;Levent Doganay,&nbsp;Mesut Akarsu,&nbsp;Zeki Karasu,&nbsp;Sabahattin Kaymakoglu,&nbsp;Fulya Gunsar","doi":"10.14744/hf.2023.2023.0011","DOIUrl":"10.14744/hf.2023.2023.0011","url":null,"abstract":"<p><p>Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease and is significantly associated with obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. NAFLD has become the most prevalent chronic liver disease in Western countries, and the proportion of NAFLD-related cirrhosis among patients on liver transplantation waiting lists has increased. In light of the accumulated data about NAFLD, and to provide a common approach with multi-disciplines dealing with the subject, it has become necessary to create new guidance for diagnosing and treating NAFLD. This guidance was prepared following an interdisciplinary study under the leadership of the Turkish Association for the Study of the Liver (TASL), Fatty Liver Special Interest Group. This new TASL Guidance is a practical application guide on NAFLD and was prepared to standardize the clinical approach to diagnosing and treating NAFLD patients. This guidance reflects many advances in the field of NAFLD. The proposals in this guidance are meant to aid decision-making in clinical practice. The guidance is primarily intended for gastroenterology, endocrinology, metabolism diseases, cardiology, internal medicine, pediatric specialists, and family medicine specialists.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort.","authors":"Omer Karasahin,&nbsp;Irem Akdemir Kalkan,&nbsp;Tuba Dal,&nbsp;Sibel Altunisik Toplu,&nbsp;Murat Harputluoglu,&nbsp;Ayse Ozlem Mete,&nbsp;Suheyla Komur,&nbsp;Figen Sarigul,&nbsp;Yesim Yildiz,&nbsp;Fatih Esmer,&nbsp;Ozlem Kandemir,&nbsp;Selcu Nazik,&nbsp;Dilara Inan,&nbsp;Fethiye Akgul,&nbsp;Safak Kaya,&nbsp;Nurettin Tunc,&nbsp;Yasar Bayindir,&nbsp;Safak Ozer Balin,&nbsp;Yesim Tasova,&nbsp;Fesih Aktar,&nbsp;Meryem Merve Oner,&nbsp;Merve Ayhan,&nbsp;Yakup Demir,&nbsp;Mustafa Kemal Celen","doi":"10.14744/hf.2022.2022.0043","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0043","url":null,"abstract":"<p><strong>Background and aim: </strong>In chronic hepatitis B infection, antiviral therapy significantly reduces the incidence of complications. This study aimed to present real-life 12-month effectiveness and safety data for TAF.</p><p><strong>Materials and methods: </strong>This Pythagoras Retrospective Cohort Study included patients from 14 centers in Turkiye. The study presents 12-month results of 480 patients treated with TAF as initial therapy or after switching from another antiviral drug.</p><p><strong>Results: </strong>The study shows treatment of about 78.1% patients with at least one antiviral agent (90.6% tenofovir disoproxil [TDF]). The rate of undetectable HBV DNA increased in both treatment-experienced and naive patients. In TDF-experienced patients, the rate of alanine transaminase (ALT) normalization increased slightly (1.6%) within 12 months, but the change was not statistically significant (p=0.766). Younger age, low albumin, and high body mass index and cholesterol were identified as risk factors for abnormal ALT after 12 months, but no linear relationship was detected. In TDF-experienced patients, renal and bone function indicators showed significant improvement three months after the transition to TAF and remained stable for 12 months.</p><p><strong>Conclusion: </strong>Real-life data demonstrated effective virological and biochemical responses with TAF therapy. After switching to TAF treatment, gains in kidney and bone functions were achieved in the early period.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/c8/hf-4-061.PMC10209973.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9917001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the effectiveness of drug-eluting transarterial chemoebolization in hepatocellular carcinoma.","authors":"Aydan Mutis Alan,&nbsp;Ozkan Alan,&nbsp;Ruslan Asadov,&nbsp;Coskun Ozer Demirtas,&nbsp;Haluk Tarik Kani,&nbsp;Perran Fulden Yumuk,&nbsp;Osman Cavit Ozdogan,&nbsp;Feyyaz Baltacioglu,&nbsp;Feyza Gunduz","doi":"10.14744/hf.2022.2022.0048","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0048","url":null,"abstract":"<p><strong>Background and aim: </strong>Transarterial Chemoembolization (TACE) therapy is currently considered as first option therapy in the intermediate stage HCC. The purpose of our study is to assess the efficacy and prognostic factors related to the DEB- TACE therapy.</p><p><strong>Materials and methods: </strong>The data from 133 patients with unresecetable HCC who were treated with DEB-TACE and followed between January 2011-March 2018 were retrospectively evaluated. To assess the efficacy of therapy, control imagings were performed at 30^th and 90^th days after the procedure. Response rates, survival outcomes, and prognostic factors were investigated.</p><p><strong>Results: </strong>According to the Barcelona staging system, 16 patients (13%) were in the early stage, 58 patients (48%) were in the intermediate stage and 48 patients (39%) were in the advanced stage. There were complete response (CR) in 20 patients (17%), partial response (PR) in 36 patients (32%), stable disease (SD) in 24 patients (21%) and progressed disease (PD) in 35 (30%) patients. Median follow-up time was 14 months (range 1-77 months). Median PFS and OS were 4 months and 11 months, respectively. In multivariate analysis, posttreatment AFP ≥400 ng/ml was found to be an independent prognostic factor on both PFS and OS. Child-Pugh classification and tumor size >7 cm were independent prognostic factors on OS.</p><p><strong>Conclusion: </strong>DEB-TACE is effective and a tolerable treatment method for unresectable HCC patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/9c/hf-4-053.PMC10209976.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9546224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report of reversible intracranial lesions after long-term Azathioprine therapy in an autoimmune hepatitis patient.","authors":"Ali Hasan Aysha,&nbsp;Elif Bulut,&nbsp;Onur Keskin","doi":"10.14744/hf.2023.2023.0006","DOIUrl":"https://doi.org/10.14744/hf.2023.2023.0006","url":null,"abstract":"<p><p>This study is written to report a case of 67-year-old female with known autoimmune hepatitis (AIH) who developed balance and walking difficulties. Clinical and imaging investigations were more suggestive of AIH suffering from lymphoproliferative disease. To identify the underlying suspected lymphoproliferative disease, series of brain scans were performed, which showed multiple brain lesions. This is a report on a striking case of multiple contrast enhanced brain lesions discovered in an AIH patient that was resolved upon withdrawal of azathioprine. Many side effects of azathioprine are acknowledged around the world; however, to the very best of our knowledge, an article on azathioprine inducing suspected malignancy was never reported.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/34/c1/hf-4-078.PMC10209979.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9916999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does mtori base immunosuppression offer survival advantage after liver transplantation for hepatocellular carcinoma? Systematic review and meta-analysis of randomized controlled trials.","authors":"Ali ALoun,&nbsp;Ez El Din Abu-Zeid,&nbsp;Ibrahim Umar Garzali","doi":"10.14744/hf.2022.2022.0049","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0049","url":null,"abstract":"<p><p>Recurrence is still a problem after liver transplant for hepatocellular carcinoma (HCC). We performed an updated systematic review and meta-analysis of randomized controlled trials comparing tumor recurrence of mammalian target of rapamycin inhibitors (mTORi) versus Calcineurin inhibitor-based immunosuppression after liver transplantation for HCC. A systematic search was conducted in the following databases: MEDLINE, EMBASE, and Cochrane Central Register of Control Trials databases. The Medical Subject Headings used in the search included: \"sirolimus,\" \"everolimus,\" \"mTORi,\" \"HCC,\" \"mTORi,\" \"hepatic transplantation\" \"randomized controlled trials,\" and \"liver transplantation (LT)\". Seven randomized controlled trials were included for meta-analysis. There were a total of 1,365 patients, with 712 of these patients receiving calcineurin inhibitors (CNIs) while 653 had received mTORi. Our meta-analysis revealed that patients that received mTORi-based immunosuppression had superior recurrence-free survival (RFS) at 1 year and 3 years with a hazard ratio of 2.02 and 1.36, respectively. Meta-analysis also showed that within the first 3 years after LT for HCC, patients receiving CNIs-based immunosuppression have a higher recurrence than those receiving mTORi-based immunosuppression. Our meta-analysis revealed that recipients of mTORi-based immunosuppression had a superior OS at 1 year and 3 years. mTORi-based immunosuppression is associated with decreased early recurrence and improved RFS and overall survival.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/8e/hf-4-082.PMC10209974.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9917000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients.","authors":"Ilkay Ergenc,&nbsp;Busra Gozaydinoglu,&nbsp;Caglayan Keklikkiran,&nbsp;Yusuf Yilmaz","doi":"10.14744/hf.2023.2023.0016","DOIUrl":"https://doi.org/10.14744/hf.2023.2023.0016","url":null,"abstract":"<p><strong>Background and aim: </strong>This study investigated the risk of the development of primary biliary cholangitis (PBC) in individuals who were incidentally identified as having positive antimitochondrial antibodies (AMA)-M2.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed extractable nuclear antibody (ENA) panel test results to identify the incidental AMA-M2-positive patients. Patients who filled the diagnostic criteria for PBC were excluded. AMA-M2-positive patients were further evaluated by physical examination, liver biochemistry, liver ultrasonography, and transient elastography (TE) and were also closely followed.</p><p><strong>Results: </strong>We included 48 (n=45, 93% female) individuals with a median age of 49 (range: 20-69) years. The median follow-up duration was 27 months (range: 9-42) after the detection of AMA-M2. Thirty-three (69%) patients had concomitant autoimmune/inflammatory disorders. Twenty-eight (58%) individuals showed seropositivity for ANA, and 21 had (43%) positive AMA. Fifteen (31%) patients developed typical PBC according to the international PBC diagnostic criteria during the follow-up, and five of them (18%) had significant fibrosis (≥8.2 kPA) by TE at the time of PBC diagnosis.</p><p><strong>Conclusion: </strong>Two-thirds of the incidental AMA-M2-positive patients developed typical features of PBC after a median 27-month follow-up. Our results suggest that AMA-M2 patients should be closely followed up to detect the late development of PBC.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/56/hf-4-069.PMC10209978.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9546223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of liver resection and living donor liver transplantation in patients with hepatocellular carcinoma within Milan criteria and well-preserved liver function.","authors":"Serdar Karakas,&nbsp;Sezai Yilmaz,&nbsp;Volkan Ince,&nbsp;Sami Akbulut,&nbsp;Yasin Dalda,&nbsp;Ayse Nur Akatli,&nbsp;Aysegul Sagir Kahraman,&nbsp;Ramazan Kutlu,&nbsp;Brian Irving Carr","doi":"10.14744/hf.2023.2023.0005","DOIUrl":"https://doi.org/10.14744/hf.2023.2023.0005","url":null,"abstract":"<p><strong>Background and aim: </strong>Liver resection (LR) and liver transplantation (LT) are curative treatments for hepatocellular carcinoma (HCC). The main purpose of this study was to compare the survival of LR and LDLT in patients with HCC within the Milan criteria.</p><p><strong>Materials and methods: </strong>The results of the LR (n=67) and LDLT (n=391) groups were compared for overall survival (OS) and disease-free survival (DFS). Twenty-six of the HCCs in the LRs met the Milan and Child A criteria. Also, 200 of the HCC patients in the LDLTs met the Milan criteria, of which 70 also met the Child A criteria.</p><p><strong>Results: </strong>Early mortality was higher in the LDLT group (13.9% vs 1.47%; p=0.003). The 5-year OS was higher in the LDLTs than the LRs, but not statistically significant (84.6% vs 74.2%; p=0.287). However, 5-year DFS was better in the LDLT group (96.8% vs 64.3%; p<0.001). When the LRs (n=26) and the LDLTs (n=70) that met both Milan and Child A criteria were compared, 5-year OS was similar (81.4% vs 74.2%; p=0.512), but DFS was better in the LDLTs (98.6% vs 64.3%; p<0.001).</p><p><strong>Conclusion: </strong>LR can be justified as the first-line treatment for HCC patients who meet Milan and Child A criteria in terms of early mortality and OS.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/76/hf-4-047.PMC10209977.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9546227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fingolimod induced fulminant liver failure requiring liver transplantation: A case report.","authors":"Ali Riza Caliskan,&nbsp;Muhsin Murat Muhip Harputluoglu,&nbsp;Emine Samdanci,&nbsp;Salih Cirik,&nbsp;Sezai Yilmaz","doi":"10.14744/hf.2022.2022.0033","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0033","url":null,"abstract":"<p><p>Fingolimod has been used for about ten years to treat multiple recurrent sclerosis. It has been reported that Fingolimod causes an elevation in liver enzymes. In this case report, the clinical and laboratory parameters improved after discontinuation of the drug. However, there is no publication in the literature regarding acute liver failure and liver transplantation following Fingolimod treatment. In this article, we presented a 33 - year - old female patient who developed acute liver failure and underwent liver transplantation after Fingolimod treatment for recurrent multiple sclerosis.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/2d/hf-4-074.PMC10209975.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9546228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}